Across TCGA pan-cancer cohorts, RNA5SP212 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RNA5SP212’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where RNA5SP212 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNA5SP212 is over-expressed in tumor.
STAD are the cancer types where RNA5SP212 tumor–normal differential expression is most reproducible.